Primary Record
Semagacestat
- In stock
- 1,281 g
- Purity
- 99.2 %
- CAS
- 425386-60-3
Compound Identifiers & Properties
- CAS
- 425386-60-3
- PubChem CID
- 9843750
- SMILES
- C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O
- Canonical SMILES
- CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21
Names & Synonyms
- Semagacestat
- 425386-60-3
- dapt
- semagacestatum
- Semagacestat?
- Semagacestat (LY450139)
- Semagacestat [USAN]
- LY450139
- LY-450139
- Semagacestat [USAN:INN]
- LY 450139
- RefChem:931602
- SEMAGACESTAT [MI]
- Semagacestat (USAN/INN)
- SEMAGACESTAT [INN]
- D01LXD
- UNII-3YN0602W4W
- 3YN0602W4W
- C19H27N3O4
- LY450139(Semagacestat)
- Semagacestat; LY450139
- MFCD09970409
- cc-411
- MLS006010180
- SCHEMBL417581
- SEMAGACESTAT [WHO-DD]
- DTXSID10235740
- CHEMBL520733
- GTPL6978
- orb1301052
- SCHEMBL29353755
- BDBM28944
- CTK8D4032
- AOB3027
- DTXCID40158231
- QCR-178
- CHEBI:131158
- PKXWXXPNHIWQHW-RCBQFDQVSA-N
- BCPP000174
- HMS3884G21
- AMY36446
- EX-A2257
- ZINC3989041
- ABP000262
- NSC755982
- s1594
- Semagacestat, 97% - 25MG 25mg
- AKOS015924574
- BCP9000888
- CB11411
- CCG-268180
- CID9843750
- CS-0292
- DB12463
- EX-1762
- FS34135
- NSC-755982
- RL03639
- CID 9950813
- NCGC00346556-01
- NCGC00346556-06
- NCGC00346556-07
- 2-(chloromethyl)indolizine-1-carbonitrile
- AC-24396
- AN-16520
- AN-37124
- AN-44989
- AS-42018
- BC683736
- HY-10009
- SC-98053
- SMR004701288
- (S)-2-hydroxy-3-methyl-N-((S)-1-((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ylamino)-1-oxopropan-2-yl)butanamide
- 866488-53-1
- AB0000748
- LY-374973
- LY-411575
- LY-424354
- TC-060612
- A8190
- LY-4501395
- NS00069725
- X7560
- J2.390.762C
- J2.730.191F
- A10836
- A25230
- D09377
- LY450139, >=98% (HPLC)
- S-1300
- 386S603
- Q426010
- L-450139
- LY450139(Semagacestat) /LY-450139/Semagacestat
- (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide
- (S)-2-Hydroxy-3-methyl-N-((S)-1-(((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)amino)-1-oxopropan-2-yl)butanamide
- (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-2-oxo-ethyl]butanamide
- (2S)-2-HYDROXY-3-METHYL-N-[(1S)-1-METHYL-2-OXO-2-[[(1S)-2,3,4,5-TETRAHYDRO-3-METHYL-2-OXO-1H-3-BENZAZEPIN-1-YL]AMINO]ETHYL]BUTANAMIDE
- LY-450139, LY450139, 425386-60-3
- (2S)-2-Hydroxy-3-methyl-N-((2S)-1-(((1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl)amino)-1-oxopropan-2-yl)butanamide
- (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide
- (2S)-2-Hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamid
- Butanamide, 2-hydroxy-3-methyl-N-((1S)-1-methyl-2-oxo-2-(((1S)-2,3,4,5-tetrahydro-3- methyl-2-oxo-1H-3-benzazepin-1-yl)amino)ethyl)-, (2S)-
- Gamma-secretase inhibitors (Alzheimer's disease), Elan Pharmaceuticals/Eli Lilly
- (1S)-1-[[(2S)-2-[[(2S)-2-Hydroxy-3-methylbutanoyl]amino]propanoyl]amino]-3-methyl-2,3,4,5-tetrahydro-1H-3-benzoazepine-2-one
- (2S)-2-HYDROXY-3-METHYL-N-((2S)-1-(((1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3- BENZAZEPIN-1-YL)AMINO)-1-OXOPROPAN-2-YL)BUTANAMIDE
- (2S)-2-hydroxy-3-methyl-N-((2S)-1-(((1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl)amino)-1-oxopropan-2-yl)butanamide
- (2S)-2-hydroxy-3-methyl-N-[(1S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]carbamoyl}ethyl]butanamide
- (2S)-2-hydroxy-3-methyl-N-[(1S)-1-{[(1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl]carbamoyl}ethyl]butanamide
- (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl]amino]-1-oxopropan-2-yl]butanamide
- (2S)-2-HYDROXY-3-METHYL-N-[(2S)-1-{[(1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-1-YL]AMINO}-1-OXOPROPAN-2-YL]BUTANAMIDE
- (2S)-N-[(1S)-1-Methyl-2-[[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzoazepine]-1-ylamino]-2-oxoethyl]-2-hydroxy-3-methylbutanamide
- (N)-((S)-2-HYDROXY-3-METHYL-BUTYRYL)-1-(L-ALANINYL)-(S)-1-AMINO-3-METHYL-2,3,4,5- TETRAHYDRO-1H-3-BENZAZEPIN-2-ONE
- (N)-((S)-2-Hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one
- (S)-N-[(S)-1-[[(3S)-2-Oxo-3-methyl-2,3,4,5-tetrahydro-1H-3-benzoazepine-1alpha-yl]carbamoyl]ethyl]-2-hydroxy-3-methylbutanamide
- BUTANAMIDE, 2-HYDROXY-3-METHYL-N-((1S)-1-METHYL-2-OXO-2-(((1S)-2,3,4,5-TETRAHYDRO-3-METHYL-2-OXO-1H-3-BENZAZEPIN-1-YL)AMINO)ETHYL)-, (2S)-
- ESF
- N(SUP 2)-((2S)-2-HYDROXY-3-METHYLBUTANOYL)-N(SUP 1)-((1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3- BENZAZEPIN-1-YL)-L-ALANINAMIDE
- N-[(1S)-2-Oxo-3-methyl-1,2,4,5-tetrahydro-3H-3-benzoazepine-1alpha-yl]-N2-[(S)-2-hydroxy-3-methylbutanoyl]-L-alaninamide
- N2-((2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-laninamide
- N2-((2S)-2-Hydroxy-3-methylbutanoyl)-N1-((1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl)-L-alaninamide